Asked by Emily

Which of the following statements BEST summarizes the evidence supporting the netarsudil/latanoprost fixed-dose combination?

It was inferior to each monotherapy in the MERCURY studies

It was superior to each component alone in reducing IOP

It is approved only to treat angle-closure glaucoma

It is dosed twice daily to improve efficacy and safety

Unsure

All Answers 1

Answered by GPT-5 mini AI
It was superior to each component alone in reducing IOP.

Explanation: In the MERCURY trials (MERCURY‑1 and MERCURY‑2) the netarsudil/latanoprost fixed‑dose combination (Rocklatan) produced greater mean IOP reductions than either netarsudil or latanoprost monotherapy. It is approved for open‑angle glaucoma/ocular hypertension and is dosed once daily (evening), not twice daily.